licensing deal Archives - PharmaDeviceNews

Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

by Venkatesh B
July 11, 2026
0 Comments

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Representative image: Respiratory medicine deal discussion highlighting Sino Biopharmaceutical’s AstraZeneca TQC3721 licensing agreement and expanded GSK inhaler commercialization rights in China.

Pharma & Biotech

Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals

by Venkatesh B
July 10, 2026
0 Comments

Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China